Ceremedy’s expert team strives to develop new treatments for CNS disorders, backed with the right medicinal chemistry and neuropharmacology experience to facilitate the full process from idea to drug candidate.


Ceremedy is a Copenhagen-based biotech company focused on drug discovery for
the treatment of CNS disorders. The company was founded in 2018 as a spin-off
from the University of Copenhagen.


We perform intelligent medicinal chemistry and structure-based drug design. With it, we target an important brain
protein with a broad range of implications for treating CNS disorders.


  • Ceremedy_group

    SUND-KU researchers and Ceremedy founders Birgitte Kornum (IN), Petrine Wellendorph (ILF) and Bente Frølund (ILF) have received a 3.5M DKK (c. 520,000 USD) pre-seed grant from the Novo Nordisk Foundation to continue and extend their efforts in CNS drug discovery. It is the second pre-seed grant for this purpose. The research will be carried out partly at SUND and partly through contract-based research.


  • In August 2018, the Novo Nordisk Foundation awarded a pre-seed grant of 3.5 mio DKK to support the research behind Ceremedy ApS. The grant is awarded to the University of Copenhagen and shared between Birgitte Kornum, Petrine Wellendorph and Bente Frølund.



Birgitte Rahbek Kornum

Associate Professor at the University of Copenhagen, with 15 years of expertise in human biology and in vivo neuroscience.

Casper Tind Hansen

Entrepeneur-in-Residence BiOrigin, with 15 years of expertise from pharma, venture investments, and management of biotech companies. Previously CEO of Pcovery ApS and part of the Novo Ventures investment.

Petrine Wellendorph

Associate Professor at the University of Copenhagen, with more than 15 years of expertise in molecular pharmacology.

Bente Frølund

VP Medicinal Chemistry
Professor at the University of Copenhagen, with more than  20 years of expertise in small-molecule medicinal chemistry.


Ceremedy ApS